# PATHFNDR FAQs

This document provides answers for FAQs from patients about the PATHFNDR studies and paltusotine.

Please note that the intake center is prepared to answer patient questions about the trial. Our intake center is staffed with a Patient Communications Team who are specifically trained to answer questions and prescreen patients for the PATHFNDR studies. Also, please remind patients that calling the intake center and speaking to someone does not obligate them to join the study.

### If I might be interested in the study or want to participate, what should I do?

The first step is to contact the intake coordinator who can tell you about the studies and, if you agree, will ask you some questions to see if you may pre-qualify. The phone number is 844-479-0315

### What's different about paltusotine?

Paltusotine is an investigational drug that, if approved, would be an option for patients looking for a once-daily oral treatment. Paltusotine is being evaluated to see if it can lower levels of growth hormone (GH) produced by the pituitary tumor and also decrease the levels of insulin-like growth factor (IGF-1) produced by the liver.

Current treatments include monthly injections and twice-daily oral tablets. If the Phase 3 studies are successful and paltusotine is approved, patients would take one oral dose of paltusotine a day.

### Will I know if I'm on the study drug or the placebo?

No. The PATHFNDR studies are double-blind studies, which means that neither the patient nor the doctor involved in the study will know who is receiving paltusotine and who is receiving the placebo. This is done to prevent any bias in the results of the trial.

### What does "Phase 3" mean?

Clinical trials are conducted in multiple steps, or phases, that are geared towards answering specific questions. The study phase dictates which questions are targeted, but safety is studied in all the phases.

During the Phase 2 studies, paltusotine was studied in a small number of acromegaly patients and was shown to maintain IGF-1 levels in both groups. In Phase 3, doctors study the efficacy of the drug in a larger group of people who have the targeted disease, in this case, acromegaly. The FDA will review the results of all the clinical studies and decide whether or not to approve the new drug for use.

# *PATHFNDR FAQs continued*

### How long is the study? How much of a commitment is it?

There are two PATHFNDR studies and the length of them can range from six to nine months, depending on the study. You'll have about 12-15 visits throughout the study and Crinetics, the company that is developing paltusotine, will pay for the study-related care and study medication costs associated with your participation in the study.

After you complete the study, you may be able to participate in a long-term open-label extension (OLE) phase for up to 96 weeks. During this part of the study, all patients will receive paltusotine at no cost. Study-related care will also be provided at no cost.

The intake center can answer your questions about the study.

### What if I live a long way from a study site?

If you live far from a study site, you may have the option to have some of the required visits conducted at your home or another suitable location. In addition, travel costs for each study participant plus one other person will be covered.

### Would I have to pay for gas and other travel costs?

Travel costs are covered for each study participant, plus one other person.

### Who's running this trial?

Crinetics Pharmaceuticals, Inc. Crinetics is a pharmaceutical company that focuses on developing treatments for rare endocrine diseases, like acromegaly. You can find more information about them at crinetics.com.

### Why do people usually participate in a study like this? And why should I consider it?

Each patient has his or her own reasons for volunteering in a clinical trial. In this case, PATHFNDR represents a chance to:

- Help doctors study whether paltusotine can control IGF-1 and GH levels, or have an effect on acromegaly symptoms
- Help advance science and treatments
- Help others who may have acromegaly
- Learn more about their acromegaly